{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:01:28Z","timestamp":1791331288113,"version":"4.3.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Treatment-free remission (TFR) has become a therapeutic objective for selected chronic-phase chronic myeloid leukemia (CP CML). However, no standardized biomarker is yet in clinical use. In this multi-center study, we explored the potential of bone marrow (BM) cytomorphology given its global accessibility and integral role in clinical diagnostics. We included diagnostic BM aspirate samples of 113 CP CML patients from seven clinical sites having attempted first TKI discontinuation. We digitized cytomorphological slides into 100x-magnified high-resolution images and analyzed these with deep learning-based image analysis. We profiled the BM cytomorphological fingerprint of CP CML patients and recapitulated the known granulocytic predominance and reduction of lymphoid, monocytic and erythroid cells in comparison to an extensive cohort of 942 control BM samples. We discovered neutrophil abundance and granulocytic maturation to associate with sustained TFR. We confirmed these visually and demonstrated their independent impact over known clinical factors. Our study underlines the potential of computational BM cytomorphology to identify novel clinical biomarkers and suggests that granulocytic expansion and maturation at diagnosis could reflect intrinsic disease pathology influencing TFR maintenance.<\/jats:p>","DOI":"10.1038\/s41375-025-02769-2","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T06:46:39Z","timestamp":1758005199000},"page":"2968-2977","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Granulocyte abundance and maturation state at diagnosis predicts treatment-free remission in CML"],"prefix":"10.1038","volume":"39","author":[{"given":"Mikko","family":"Purhonen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael","family":"Tatun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katariina","family":"Luukkainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9354-5864","authenticated-orcid":false,"given":"Kevin","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8145-9994","authenticated-orcid":false,"given":"Henri","family":"Sundquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oda","family":"Tafjord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stina","family":"S\u00f6derlund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6205-7799","authenticated-orcid":false,"given":"Shady","family":"Adnan-Awad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anni","family":"Dohlen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Heikkinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perttu","family":"Koskenvesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanna","family":"Siitonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0816-8241","authenticated-orcid":false,"given":"Satu","family":"Mustjoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5895-8797","authenticated-orcid":false,"given":"Naranie","family":"Shanmuganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coral","family":"Bryce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Signe","family":"Danielsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2670-5696","authenticated-orcid":false,"given":"Henrik","family":"Hjorth-Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulla","family":"Olsson-Str\u00f6mberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kumagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1717-6208","authenticated-orcid":false,"given":"Shinya","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7171-2935","authenticated-orcid":false,"given":"David M.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7842-9419","authenticated-orcid":false,"given":"Oscar","family":"Br\u00fcck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,16]]},"reference":[{"key":"2769_CR1","doi-asserted-by":"publisher","first-page":"4808","DOI":"10.1182\/blood-2008-07-077958","volume":"112","author":"BJ Druker","year":"2008","unstructured":"Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood. 2008;112:4808\u201317.","journal-title":"Blood"},{"key":"2769_CR2","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966\u201384.","journal-title":"Leukemia"},{"key":"2769_CR3","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","volume":"34","author":"H Bower","year":"2016","unstructured":"Bower H, Bj\u00f6rkholm M, Dickman PW, H\u00f6glund M, Lambert PC, Andersson TM-L. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34:2851\u20137.","journal-title":"J Clin Oncol"},{"key":"2769_CR4","doi-asserted-by":"publisher","first-page":"e528","DOI":"10.1016\/S2352-3026(15)00196-9","volume":"2","author":"J Imagawa","year":"2015","unstructured":"Imagawa J, Tanaka H, Okada M, Nakamae H, Hino M, Murai K, et al. Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial. Lancet Haematol. 2015;2:e528\u2013e535.","journal-title":"Lancet Haematol"},{"key":"2769_CR5","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ejca.2017.02.028","volume":"77","author":"L Campiotti","year":"2017","unstructured":"Campiotti L, Suter MB, Guasti L, Piazza R, Gambacorti-Passerini C, Grandi AM, et al. Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: a systematic review and a meta-analysis. Eur J Cancer. 2017;77:48\u201356.","journal-title":"Eur J Cancer"},{"key":"2769_CR6","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1038\/leu.2017.63","volume":"31","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Masszi T, Giles FJ, Radich JP, Ross DM, G\u00f3mez Casares MT, et al. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study. Leukemia. 2017;31:1525\u201331.","journal-title":"Leukemia"},{"key":"2769_CR7","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1182\/blood-2016-09-742205","volume":"129","author":"D Rea","year":"2017","unstructured":"Rea D, Nicolini FE, Tulliez M, Guilhot F, Guilhot J, Guerci-Bresler A, et al. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study. Blood. 2017;129:846\u201354.","journal-title":"Blood"},{"key":"2769_CR8","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"F-X Mahon","year":"2010","unstructured":"Mahon F-X, R\u00e9a D, Guilhot J, Guilhot F, Huguet F, Nicolini F, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11:1029\u201335.","journal-title":"Lancet Oncol"},{"key":"2769_CR9","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","volume":"19","author":"S Saussele","year":"2018","unstructured":"Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018;19:747\u201357.","journal-title":"Lancet Oncol"},{"key":"2769_CR10","doi-asserted-by":"publisher","first-page":"717","DOI":"10.3324\/haematol.2015.139899","volume":"101","author":"SE Lee","year":"2016","unstructured":"Lee SE, Choi SY, Song HY, Kim SH, Choi MY, Park JS, et al. Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study. Haematologica. 2016;101:717\u201323.","journal-title":"Haematologica"},{"key":"2769_CR11","doi-asserted-by":"publisher","first-page":"e375","DOI":"10.1016\/S2352-3026(19)30094-8","volume":"6","author":"RE Clark","year":"2019","unstructured":"Clark RE, Polydoros F, Apperley JF, Milojkovic D, Rothwell K, Pocock C, et al. De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial. Lancet Haematol. 2019;6:e375\u2013e383.","journal-title":"Lancet Haematol"},{"key":"2769_CR12","doi-asserted-by":"publisher","first-page":"903","DOI":"10.3324\/haematol.2011.056853","volume":"97","author":"N Takahashi","year":"2012","unstructured":"Takahashi N, Kyo T, Maeda Y, Sugihara T, Usuki K, Kawaguchi T, et al. Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia. Haematologica. 2012;97:903\u20136.","journal-title":"Haematologica"},{"key":"2769_CR13","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7326\/M17-1094","volume":"168","author":"F-X Mahon","year":"2018","unstructured":"Mahon F-X, Boquimpani C, Kim D-W, Benyamini N, Clementino NCD, Shuvaev V, et al. Treatment-free remission after second-line nilotinib treatment in patients with chronic myeloid leukemia in chronic phase. Ann Intern Med. 2018;168:461\u201370.","journal-title":"Ann Intern Med"},{"key":"2769_CR14","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1002\/ajh.26550","volume":"97","author":"FG Haddad","year":"2022","unstructured":"Haddad FG, Sasaki K, Issa GC, Garcia-Manero G, Ravandi F, Kadia T, et al. Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors. Am J Hematol. 2022;97:856\u201364.","journal-title":"Am J Hematol"},{"key":"2769_CR15","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.3324\/haematol.2017.165001","volume":"102","author":"D Rea","year":"2017","unstructured":"Rea D, Henry G, Khaznadar Z, Etienne G, Guilhot F, Nicolini F, et al. Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study. Haematologica. 2017;102:1368\u201377.","journal-title":"Haematologica"},{"key":"2769_CR16","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1038\/leu.2016.360","volume":"31","author":"M Ilander","year":"2017","unstructured":"Ilander M, Olsson-Str\u00f6mberg U, Schlums H, Guilhot J, Br\u00fcck O, L\u00e4hteenm\u00e4ki H, et al. Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia. Leukemia. 2017;31:1108\u201316.","journal-title":"Leukemia"},{"key":"2769_CR17","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1182\/blood-2011-04-348110","volume":"118","author":"E Jabbour","year":"2011","unstructured":"Jabbour E, Kantarjian H, O\u2019Brien S, Shan J, Quintas-Cardama A, Faderl S, et al. The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. Blood. 2011;118:4541\u20136.","journal-title":"Blood"},{"key":"2769_CR18","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1182\/blood-2014-03-566323","volume":"124","author":"S Branford","year":"2014","unstructured":"Branford S, Yeung DT, Parker WT, Roberts ND, Purins L, Braley JA, et al. Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. Blood. 2014;124:511\u20138.","journal-title":"Blood"},{"key":"2769_CR19","doi-asserted-by":"publisher","first-page":"4437","DOI":"10.1182\/blood-2008-06-162388","volume":"112","author":"D Marin","year":"2008","unstructured":"Marin D, Milojkovic D, Olavarria E, Khorashad JS, De Lavallade H, Reid AG, et al. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood. 2008;112:4437\u201344.","journal-title":"Blood"},{"key":"2769_CR20","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1038\/leu.2014.153","volume":"28","author":"B Hanfstein","year":"2014","unstructured":"Hanfstein B, Shlyakhto V, Lauseker M, Hehlmann R, Saussele S, Dietz C, et al. Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib. Leukemia. 2014;28:1988\u201392.","journal-title":"Leukemia"},{"key":"2769_CR21","doi-asserted-by":"publisher","unstructured":"Shanmuganathan N, Pagani IS, Ross DM, Park S, Yong ASM, Braley JA, et al. Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia. Blood 137:2021 https:\/\/doi.org\/10.1182\/blood.2020005514.","DOI":"10.1182\/blood.2020005514"},{"key":"2769_CR22","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1158\/2643-3230.BCD-20-0162","volume":"2","author":"OE Br\u00fcck","year":"2021","unstructured":"Br\u00fcck OE, Lallukka-Br\u00fcck SE, Hohtari HR, Ianevski A, Ebeling FT, Kovanen PE, et al. Machine learning of bone marrow histopathology identifies genetic and clinical determinants in patients with MDS. Blood Cancer Discov. 2021;2:239\u201349.","journal-title":"Blood Cancer Discov"},{"key":"2769_CR23","doi-asserted-by":"publisher","first-page":"e0000187","DOI":"10.1371\/journal.pdig.0000187","volume":"2","author":"M Hehr","year":"2023","unstructured":"Hehr M, Sadafi A, Matek C, Lienemann P, Pohlkamp C, Haferlach T, et al. Explainable AI identifies diagnostic cells of genetic AML subtypes. PLoS Digital Health. 2023;2:e0000187.","journal-title":"PLoS Digital Health"},{"key":"2769_CR24","doi-asserted-by":"publisher","first-page":"16591","DOI":"10.1109\/ACCESS.2021.3053408","volume":"9","author":"W Weng","year":"2015","unstructured":"Weng W, Zhu X. U-Net: convolutional networks for biomedical image segmentation. IEEE Access. 2015;9:16591\u2013603.","journal-title":"IEEE Access"},{"key":"2769_CR25","doi-asserted-by":"crossref","unstructured":"Redmon J, Divvala S, Girshick R, Farhadi A. You only look once: unified, real-time object detection. Proceedings of the IEEE Computer Society Conference on Computer Vision and Pattern Recognition 2015;2016:779\u201388.","DOI":"10.1109\/CVPR.2016.91"},{"key":"2769_CR26","unstructured":"Dosovitskiy A, Beyer L, Kolesnikov A, Weissenborn D, Zhai X, Unterthiner T, et al. An Image is Worth 16x16 Words: transformers for image recognition at scale. ICLR 2021 - 9th International Conference on Learning Representations 2020. https:\/\/arxiv.org\/abs\/2010.11929v2."},{"key":"2769_CR27","doi-asserted-by":"crossref","unstructured":"Assran M, Caron M, Misra I, Bojanowski P, Bordes F, Vincent P, et al. Masked siamese networks for label-efficient learning. Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics) 2022;13691 LNCS:456\u201373.","DOI":"10.1007\/978-3-031-19821-2_26"},{"key":"2769_CR28","doi-asserted-by":"crossref","unstructured":"Bhatia R Chronic Myeloid Leukemia. Hematology: Basic Principles and Practice 2018; 1055-70.","DOI":"10.1016\/B978-0-323-35762-3.00067-6"},{"key":"2769_CR29","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.3390\/clinpract14040097","volume":"14","author":"H Ureshino","year":"2024","unstructured":"Ureshino H, Takeda Y, Kamachi K, Ono T, Iriyama N, Ohtsuka E, et al. A higher neutrophil count is associated with favorable achievement of treatment-free remission in patients with chronic myeloid leukemia who received second generation tyrosine kinase inhibitor as frontline treatment. Clin Pr. 2024;14:1216\u201324.","journal-title":"Clin Pr"},{"key":"2769_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-022-00667-9","volume":"12","author":"S Adnan Awad","year":"2022","unstructured":"Adnan Awad S, Br\u00fcck O, Shanmuganathan N, Jarvinen T, L\u00e4hteenm\u00e4ki H, Klievink J, et al. Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation. Blood Cancer J. 2022;12:1\u20134.","journal-title":"Blood Cancer J"},{"key":"2769_CR31","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.3324\/haematol.2018.193086","volume":"103","author":"K Srutova","year":"2018","unstructured":"Srutova K, Curik N, Burda P, Savvulidi F, Silvestri G, Trotta R, et al. BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia. Haematologica. 2018;103:2016\u201325.","journal-title":"Haematologica"},{"key":"2769_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-021-03826-1","volume":"12","author":"YK Fu","year":"2021","unstructured":"Fu YK, Tan Y, Wu B, Dai YT, Xu XG, Pan MM, et al. Gata2-L359V impairs primitive and definitive hematopoiesis and blocks cell differentiation in murine chronic myelogenous leukemia model. Cell Death Dis. 2021;12:1\u201317.","journal-title":"Cell Death Dis"},{"key":"2769_CR33","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41568-020-0281-y","volume":"20","author":"S Jaillon","year":"2020","unstructured":"Jaillon S, Ponzetta A, Di Mitri D, Santoni A, Bonecchi R, Mantovani A. Neutrophil diversity and plasticity in tumour progression and therapy. Nature Rev Cancer. 2020;20:485\u2013503.","journal-title":"Nature Rev Cancer"},{"key":"2769_CR34","doi-asserted-by":"publisher","first-page":"6606","DOI":"10.1158\/1078-0432.CCR-18-3373","volume":"25","author":"FE Nicolini","year":"2019","unstructured":"Nicolini FE, Dulucq S, Boureau L, Cony-Makhoul P, Charbonnier A, Escoffre-Barbe M, et al. Evaluation of residual disease and TKI duration are critical predictive factors for molecular recurrence after stopping imatinib first-line in chronic phase CML patients. Clinical Cancer Res. 2019;25:6606\u201313.","journal-title":"Clinical Cancer Res"},{"key":"2769_CR35","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1200\/JCO.23.01647","volume":"42","author":"FX Mahon","year":"2024","unstructured":"Mahon FX, Pfirrmann M, Dulucq S, Hochhaus A, Panayiotidis P, Almeida A, et al. European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in chronic myeloid leukemia: final analysis and novel prognostic factors for treatment-free remission. J Clin Oncol. 2024;42:1875\u201380.","journal-title":"J Clin Oncol"},{"key":"2769_CR36","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/s41551-023-01049-7","volume":"7","author":"S Azizi","year":"2023","unstructured":"Azizi S, Culp L, Freyberg J, Mustafa B, Baur S, Kornblith S, et al. Robust and data-efficient generalization of self-supervised machine learning for diagnostic imaging. Nat Biomed Eng. 2023;7:756\u201379.","journal-title":"Nat Biomed Eng"},{"key":"2769_CR37","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.3324\/haematol.2022.280811","volume":"107","author":"S Dulucq","year":"2022","unstructured":"Dulucq S, Nicolini FE, Rea D, Cony-Makhoul P, Charbonnier A, Escoffre-Barbe M, et al. Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial. Haematologica. 2022;107:2859\u201369.","journal-title":"Haematologica"},{"key":"2769_CR38","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1093\/jnci\/djab184","volume":"114","author":"KL Schoenbeck","year":"2022","unstructured":"Schoenbeck KL, Atallah E, Lin L, Weinfurt KP, Cortes J, Deininger MWN, et al. Patient-reported functional outcomes in patients with chronic myeloid leukemia after stopping tyrosine kinase inhibitors. J Natl Cancer Inst. 2022;114:160\u20134.","journal-title":"J Natl Cancer Inst"},{"key":"2769_CR39","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1111\/cas.14430","volume":"111","author":"K Yamazaki","year":"2020","unstructured":"Yamazaki K, Inagaki N, Moldaver D, Viana R, Kimura S. Budget impact analysis of treatment-free remission in nilotinib-treated Japanese chronic myeloid leukemia patients. Cancer Sci. 2020;111:2526\u201335.","journal-title":"Cancer Sci"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02769-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02769-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02769-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T09:10:41Z","timestamp":1763629841000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02769-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,16]]},"references-count":39,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2769"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02769-2","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,16]]},"assertion":[{"value":"21 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"OB declares research funding (Pfizer and Gilead Sciences), consultancy fees (AstraZeneca, Novartis, Sanofi, Astellas Pharma, GSK, and Amgen), stock ownership (Cellbytes Ltd). SaS reports stock ownership (Cellbytes Ltd). SA-A reports research funding (Orion Research Foundation). SM reports research funding (BMS, Novartis, Pfizer) and consultancy fees (Novartis, DrenBio) (all unrelated to this study). HH-H reports research funding from Pfizer, Incyte, BMS and Austrian Orphan to the Nordic CML study group (all unrelated to this study). DR has received honoraria from Merck and Novartis and has had an advisory role for Merck, Menarini, Novartis, and Takeda (all unrelated to this study). NS reports honoraria from Novartis and Mallinckrodt.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}